Skip to content

San Gabriel Valley Tribune

70°F
Tuesday, January 13th 2026

e-Edition

Trending:

Recent Quotes
My Watchlist
Indicators
Local Stocks
San Gabriel Valley
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Foghorn Therapeutics Inc. - Common Stock (NQ:FHTX)

6.670 +0.290 (+4.55%)
Streaming Delayed Price Updated: 12:36 PM EST, Jan 13, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Foghorn Therapeutics Inc. - Common Stock

< Previous 1 2 3 4 5 6 Next >
News headline image
Foghorn Therapeutics Highlights January Equity Financing, Program Progress and Strategic Objectives for 2026
From Foghorn Therapeutics, Inc.
Via GlobeNewswire
News headline image
Foghorn Therapeutics to Participate in the 8th Annual Evercore Healthcare Conference
From Foghorn Therapeutics, Inc.
Via GlobeNewswire
News headline image
This Aardvark Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Friday ↗
 
Via Benzinga
News headline image
Foghorn Therapeutics Provides Third Quarter 2025 Financial and Corporate Update
From Foghorn Therapeutics, Inc.
Via GlobeNewswire
News headline image
These stocks are gapping in today's session ↗
Investors and traders are closely monitoring the gap up and gap down stocks in today's session on Tuesday. Let's explore the market movements and identify the stocks with significant gaps. 
Via Chartmill
News headline image
Foghorn Therapeutics to Participate in Three Upcoming Investor Conferences
From Foghorn Therapeutics, Inc.
Via GlobeNewswire
News headline image
Foghorn Therapeutics Announces Updates for Selective ARID1B, Selective CBP and Selective EP300 Degrader Programs
From Foghorn Therapeutics, Inc.
Via GlobeNewswire
News headline image
Foghorn Therapeutics Announces Significant Progress for Selective ARID1B Degrader at the 8th Annual TPD and Induced Proximity Summit
Foghorn to host a virtual investor event on updates for its Selective ARID1B, Selective CBP and Selective EP300 degrader programs on Thursday October 30, 2025, at 12 p.m. EDT 
From Foghorn Therapeutics, Inc.
Via GlobeNewswire
News headline image
Foghorn Therapeutics to Participate in Three Upcoming Investor Conferences
From Foghorn Therapeutics, Inc.
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Monday's After-Market Session ↗
 
Via Benzinga
News headline image
Foghorn Therapeutics Provides Second Quarter 2025 Financial and Corporate Update
From Foghorn Therapeutics, Inc.
Via GlobeNewswire
News headline image
Foghorn Therapeutics to Participate in Four Upcoming Investor Conferences
From Foghorn Therapeutics, Inc.
Via GlobeNewswire
News headline image
Foghorn Therapeutics Provides First Quarter 2025 Financial and Corporate Update
From Foghorn Therapeutics, Inc.
Via GlobeNewswire
News headline image
Foghorn Therapeutics to Participate in the Citizens Life Sciences Conference
From Foghorn Therapeutics, Inc.
Via GlobeNewswire
News headline image
Foghorn Therapeutics Appoints Neil Gallagher and Stuart Duty to its Board of Directors
From Foghorn Therapeutics, Inc.
Via GlobeNewswire
News headline image
Foghorn Therapeutics Presents New Preclinical Data on Selective SMARCA2 Inhibitor FHD-909 and Selective CBP and Selective EP300 Degrader Programs and Provides Pipeline Update
From Foghorn Therapeutics, Inc.
Via GlobeNewswire
News headline image
This PayPal Analyst Begins Coverage On A Bearish Note; Here Are Top 5 Initiations For Wednesday ↗
 
Via Benzinga
News headline image
Foghorn Therapeutics to Host Virtual Investor Event to Review Pipeline Updates in Conjunction with 2025 AACR Annual Meeting
From Foghorn Therapeutics, Inc.
Via GlobeNewswire
News headline image
Why PVH Shares Are Trading Higher By Around 15%; Here Are 20 Stocks Moving Premarket ↗
 
Via Benzinga
News headline image
Foghorn Therapeutics Announces New Preclinical Data for Selective SMARCA2 Inhibitor FHD-909 and Selective CBP and EP300 Degrader Programs at 2025 AACR Meeting
From Foghorn Therapeutics, Inc.
Via GlobeNewswire
News headline image
Foghorn Therapeutics Provides Financial Update for 2024 and 2025 Strategic Outlook
From Foghorn Therapeutics, Inc.
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
This Worthington Enterprises Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday ↗
 
Via Benzinga
News headline image
Foghorn Therapeutics Highlights Program Progress and Strategic Objectives for 2025
From Foghorn Therapeutics, Inc.
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Monday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Why Foghorn Therapeutics (FHTX) Stock Is Trading Lower ↗
Foghorn Therapeutics shares are trading lower by 20.2% during Monday's session. The company announced it will discontinue independent development of its FHD-286 program. 
Via Benzinga
News headline image
Foghorn Therapeutics Provides Update on FHD-286 Clinical Development Program and Strategic Priorities
From Foghorn Therapeutics, Inc.
Via GlobeNewswire
News headline image
Foghorn Therapeutics to Participate in Three Upcoming Investor Conferences
From Foghorn Therapeutics, Inc.
Via GlobeNewswire
News headline image
Foghorn Therapeutics Provides Third Quarter 2024 Financial and Corporate Update
From Foghorn Therapeutics, Inc.
Via GlobeNewswire
News headline image
Foghorn Therapeutics Announces First Patient Dosed with First-in-Class Oral SMARCA2 Selective Inhibitor FHD-909 in a Phase 1 Trial for SMARCA4 Mutated Solid Tumors
From Foghorn Therapeutics, Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.